Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Lantheus Holdings (LNTH) closed at $79.28, indicating a -0.78% shift from the previous trading day.
Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?
Lantheus Holdings (LNTH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for May 31st
MNSO, LNTH and LXFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 31, 2023.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think "Yes"
Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade
The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Lantheus Holdings (LNTH) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
Lantheus Holdings, Inc. excels in radiopharmaceuticals, with PYLARIFY's dominance in PSMA PET imaging. The market for radiopharmaceuticals is expanding beyond all expectations by both industry experts and the company's management. Lantheus is actively expanding its pipeline by making strategic investments backed by a robust balance sheet.
